BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11285271)

  • 1. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates.
    Chun W; Lesort M; Tucholski J; Ross CA; Johnson GV
    J Cell Biol; 2001 Apr; 153(1):25-34. PubMed ID: 11285271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
    Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
    Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does tissue transglutaminase play a role in Huntington's disease?
    Lesort M; Chun W; Tucholski J; Johnson GV
    Neurochem Int; 2002 Jan; 40(1):37-52. PubMed ID: 11738471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calmodulin regulates transglutaminase 2 cross-linking of huntingtin.
    Zainelli GM; Ross CA; Troncoso JC; Fitzgerald JK; Muma NA
    J Neurosci; 2004 Feb; 24(8):1954-61. PubMed ID: 14985437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
    Cooper JK; Schilling G; Peters MF; Herring WJ; Sharp AH; Kaminsky Z; Masone J; Khan FA; Delanoy M; Borchelt DR; Dawson VL; Dawson TM; Ross CA
    Hum Mol Genet; 1998 May; 7(5):783-90. PubMed ID: 9536081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
    Zainelli GM; Ross CA; Troncoso JC; Muma NA
    J Neuropathol Exp Neurol; 2003 Jan; 62(1):14-24. PubMed ID: 12528814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.
    Kim M; Lee HS; LaForet G; McIntyre C; Martin EJ; Chang P; Kim TW; Williams M; Reddy PH; Tagle D; Boyce FM; Won L; Heller A; Aronin N; DiFiglia M
    J Neurosci; 1999 Feb; 19(3):964-73. PubMed ID: 9920660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
    Zainelli GM; Dudek NL; Ross CA; Kim SY; Muma NA
    J Neuropathol Exp Neurol; 2005 Jan; 64(1):58-65. PubMed ID: 15715085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
    Lunkes A; Mandel JL
    Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear targeting of mutant Huntingtin increases toxicity.
    Peters MF; Nucifora FC; Kushi J; Seaman HC; Cooper JK; Herring WJ; Dawson VL; Dawson TM; Ross CA
    Mol Cell Neurosci; 1999 Aug; 14(2):121-8. PubMed ID: 10479410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue transglutaminase is not involved in the aggregate formation of stably expressed alpha-synuclein in SH-SY5Y human neuroblastoma cells.
    Suh MD; Park CH; Kim SS; Kil MO; Lee GH; Johnson GV; Chun W
    Arch Pharm Res; 2004 Aug; 27(8):850-6. PubMed ID: 15460447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.
    Dudek NL; Dai Y; Muma NA
    Brain Pathol; 2010 Jan; 20(1):176-89. PubMed ID: 19338577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of neurite outgrowth and promotion of cell death by cytoplasmic soluble mutant huntingtin stably transfected in mouse neuroblastoma cells.
    Ye C; Zhang Y; Wang W; Wang J; Li H
    Neurosci Lett; 2008 Sep; 442(1):63-8. PubMed ID: 18650014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
    Hazeki N; Nakamura K; Goto J; Kanazawa I
    Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense downregulation of mutant huntingtin in a cell model.
    Hasholt L; Abell K; Nørremølle A; Nellemann C; Fenger K; Sørensen SA
    J Gene Med; 2003 Jun; 5(6):528-38. PubMed ID: 12797118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.
    Li SH; Li XJ
    Hum Mol Genet; 1998 May; 7(5):777-82. PubMed ID: 9536080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease.
    Busch A; Engemann S; Lurz R; Okazawa H; Lehrach H; Wanker EE
    J Biol Chem; 2003 Oct; 278(42):41452-61. PubMed ID: 12888569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.
    Hackam AS; Hodgson JG; Singaraja R; Zhang T; Gan L; Gutekunst CA; Hersch SM; Hayden MR
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1047-55. PubMed ID: 10434304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.
    Hackam AS; Singaraja R; Zhang T; Gan L; Hayden MR
    Hum Mol Genet; 1999 Jan; 8(1):25-33. PubMed ID: 9887328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.